• Trial Update

A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma

Updated: Apr 26

A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma


lintuzumab

Establish the MTD of Lintuzumab-Ac225 as monotherapy

Establish overall response rate (ORR) where ORR = CR + sCR+ VGPR+PR)

Confirm the safety profile of the treatment regimen

Estimate progression-free survival (PFS) and overall survival


Sponsor:

Actinium Pharmaceuticals

 

Official Title: A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma

First Posted : December 20, 2016


https://clinicaltrials.gov/ct2/show/NCT02998047

 

Actinium Ac 225 Lintuzumab


Actinium Ac 225 Lintuzumab (Code C82414)


225Ac-HuM195

Actinium (225Ac) Lintuzumab Satetraxetan

Actinium Ac 225 Lintuzumab

Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195

LINTUZUMAB SATETRAXETAN AC-225

SGN-33 AC-225

 

Locations

United States, California

United States, Kansas

United States, New York

United States, Texas

United States, Wisconsin



Posts Archive